What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on (loss of) one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform…
ID
Bron
Verkorte titel
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. This outcome is assessed at regular time intervals until 12 months after recruitment.
Achtergrond van het onderzoek
In the European First Episode Schizophrenia Trial (EUFEST) we study the effectiveness of antipsychotic drugs in patients with recent onset schizophrenia. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention. We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.
The principal investigators are Prof.dr. René S Kahn and Prof.dr. W Wolfgang Fleischhacker.
Doel van het onderzoek
What is the effectiveness of low doses of
haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on (loss of) one year retention in patients with recent onset of schizophrenia, schizoaffective, and
schizophreniform disorder?
Onderzoeksproduct en/of interventie
Drug: Amisulpride 200-800 mg/day
Drug: Haloperidol 1-4 mg/day
Drug: Olanzapine 5-20 mg/day
Drug: Quetiapine 200-750 mg/day
Drug: Ziprasidone 40-160 mg/day
Publiek
P.O. Box 85500
Han Boter
Utrecht 3508 GA
The Netherlands
+31 (0)30 2509046
h.boter@azu.nl
Wetenschappelijk
P.O. Box 85500
Han Boter
Utrecht 3508 GA
The Netherlands
+31 (0)30 2509046
h.boter@azu.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Diagnosis of schizophrenia;
2. Schizophreniform or schizoaffective disorder;
3. Age 18-40 years.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. A time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years;
2. Prior use of antipsychotic medication longer than an episode of two weeks in the previous year and/or 6 weeks lifetime;
3. Intolerance to one of the drugs in this study;
4. The presence of one or more of the contraindications against any of the study drugs.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL10 |
| NTR-old | NTR25 |
| Ander register | : N/A |
| ISRCTN | ISRCTN68736636 |
Samenvatting resultaten
<br>
Fleischhacker WW, Keet IP, Kahn RS. The European First Episode
Schizophrenia Trial (EUFEST): Rationale and design of the trial.
Schizophr Res 2005;78:147-56.